Business Wire

SOUNDREEF

21.3.2024 20:10:32 CET | Business Wire | Press release

Share
Soundreef Celebrates a Milestone for Copyright Management in Italy and Europe

The European Court of Justice has issued a groundbreaking decision that opens the Italian copyright management market to Independent Management Entities. Soundreef, a leading independent management entity in Europe, celebrates this significant victory for the rights of authors, composers, and publishers to choose their representation in the copyright management sector.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321014981/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Davide d'Atri - Soundreef CEO (Photo: Business Wire)

The Court ruling reads:

“In its judgment, the Court replies that, in so far as the national legislation at issue does not allow independent management entities established in another Member State to provide their copyright management services in Italy, it constitutes a restriction on the freedom to provide services. Although that restriction may in principle be justified by the overriding objective of protecting intellectual property rights, it is not proportionate, as it generally and absolutely precludes any independent management entity established in another Member State from carrying out its activity in the market concerned. The Court points out that measures that are less restrictive of the freedom to provide services might enable the objective to be attained. Consequently, the Court finds that the Italian legislation at issue is not compatible with EU law.

This decision highlights the importance of a liberalized market that welcomes private entities, promoting innovation and offering rightsholders improved management options.

Soundreef has played a crucial role in supporting this change over the last 10 years, together with industry partners, to ensure a more efficient, fair, and forward-looking copyright ecosystem. Soundreef is also the first independent management entity in Europe with a fully operational collection network, ready to leverage this new opportunity to enhance its services to authors, composers, and publishers.

Soundreef already represents over 43,000 songwriters and publishers globally, with 26,000 hailing from Italy. This includes stars such as Gigi D’Alessio, J-AX, Laura Pausini, Ultimo, Alejandro Sanz, and Sfera Ebbasta; heritage and contemporary writers like Giancarlo Bigazzi, Maurizio Fabrizio, Takagi & Ketra, and Federica Abbate; as well as some of the most important Italian rap artists and film and TV composers. In addition, SESAC Performing Rights has chosen Soundreef to represent its extensive repertoire in Italy, effective January 1, 2024. Founded in 1930, SESAC Performing Rights currently licenses the public performance of thousands of chart-topping songs on behalf of its top-tier affiliated songwriters and music publishers, which include such familiar names as Bob Dylan, Neil Diamond, Adele, Jack Harlow, Ariana Grande, Disclosure, Zac Brown, Rosanne Cash, Lee Brice, Margo Price, Nicky Jam, Blanco Brown, and many more. SESAC has also long represented the music on some of TV’s biggest shows including Grey’s Anatomy, How I Met Your Mother, A Million Little Things, Manifest, Dateline NBC, Dr. Phil, Seinfeld, and Modern Family, and is the PRO of choice among many of Hollywood’s most sought-after film and television composers including Christophe Beck, Danny Lux, The Newton Brothers, John Ehrlich, Gabriel Mann, Lili Haydn, and Guillermo Brown among others.

E-Lex is, from the very beginning, the law firm that assisted Soundreef in the main disputes in the field of copyright and copyright management. The team, initially led by Guido Scorza (now a member of the Italian Data Protection Authority), is now composed by Professor Giovanni Maria Riccio, the lawyer Adriana Peduto, partners in the firm, and the lawyer Dario Malandrino.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240321014981/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye